S
Sylvie Negrier
Researcher at University of Lyon
Publications - 290
Citations - 30574
Sylvie Negrier is an academic researcher from University of Lyon. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 59, co-authored 275 publications receiving 28316 citations. Previous affiliations of Sylvie Negrier include French Institute of Health and Medical Research & Lyons.
Papers
More filters
Journal ArticleDOI
Open-Label Phase II Trial of First-Line Everolimus Monotherapy in Patients with Advanced Papillary Renal Cell Carcinoma: Raptor Interim Analysis
Bernard Escudier,Sergio Bracarda,J. P. Maroto,Cezary Szczylik,Paul Nathan,Sylvie Negrier,K. Slimane,C. May,C. Porta,Viktor Grünwald +9 more
TL;DR: Results of this interim analysis have demonstrated that everolimus provides clinical benefit to patients with advanced papillary RCC, and support the further evaluation ofEverolimus as a first-line treatment option for patients withadvanced papillaryRCC.
Journal ArticleDOI
Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.
Manon de Vries-Brilland,Marine Gross-Goupil,Elouen Boughalem,Benoit Beuselinck,Constance Thibault,Christine Chevreau,Sylvain Ladoire,Philippe Barthélémy,Sylvie Negrier,Delphine Borchiellini,Olivier Huillard,Lionnel Geoffrois,Gwenaelle Gravis,Carolina Saldana,Antoine Thiery-Vuillemin,Valérie Seegers,Bernard Escudier,Alain Ravaud,Laurence Albiges +18 more
TL;DR: PD-1i exhibit limited activity in this pRCC population, with better TTF and ORR in type 1 pR CC, underline the need for further prospective clinical trials evaluating ICI combinations in pts with pRcc.
Journal ArticleDOI
7123 First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival
Bohuslav Melichar,Sergio Bracarda,Joaquim Bellmunt,Alain Ravaud,Sylvie Negrier,S. Jethwa,Bernard Escudier +6 more
Journal ArticleDOI
Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States
Agnes Benedict,Robert A. Figlin,Claudie Charbonneau,Noemi Kreif,Subramanian Hariharan,Sylvie Negrier +5 more
TL;DR: In this article, the most prevalent kidney cancer, RCC, is a relatively rare malignancy that carries a poor prognosis and new targeted therapies, such as sunitinib, sorafenib, temsirolimus, and beva...
Journal ArticleDOI
Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
Frede Donskov,Robert J. Motzer,Eric Voog,Elizabeth Hovey,Carsten Grüllich,Louise M. Nott,Katharine Cuff,Thierry Gil,Niels Viggo Jensen,Christine Chevreau,Sylvie Negrier,Reinhard Depenbusch,Lothar Bergmann,Izzy Cornelio,Anne Champsaur,Bernard Escudier,Sumanta K. Pal,Thomas Powles,Toni K. Choueiri +18 more
TL;DR: Evaluated the impact of changes in target lesion size from baseline on OS in patients with advanced RCC who had received prior VEGFR TKI therapy and found the rate of target lesions regression was higher in the MSKCC risk group.